Crystal structure of (η 6-1-isopropyl-4-methyl benzene)-(N-(2,5-dichlorophenyl)-1-(pyridin-2-yl)methanimine-κ2 N,N′)ruthenium(II) perchlorate, C22H22Cl4N2O4Ru

C22H22Cl4N2O4Ru, monoclinic, P21/c (no. 14), a = 15.0181(3) Å, b = 10.3983(2) Å, c = 16.6496(3) Å, β = 112.459(1)°, V = 2402.84(8) Å3, Z = 4, R gt(F) = 0.0180, wR ref(F 2) = 0.0474, T = 173(2) K.

Synthesis, characterization, anticancer and antimicrobial study of arene ruthenium(II) complexes with 1,2,4-triazole ligands containing an α-diimine moiety

The reaction of the ruthenium arene dimers [(η 6-arene)Ru(μ-Cl)Cl]2 (where arene=benzene or p-cymene) with the ligands 4-benzylidene-3,5-di(2′-pyridyl)-4-amino-1,2,4-triazole (L1 ), 2-methoxybenzylidene-3,5-di(2′-pyridyl)-4-amino-1,2,4-triazole (L2 ), 4-methylbenzylidene-3,5-di(2′-pyridyl)-4-amino-1,2,4-triazole (L3 ) and indole-3-carbaldehyde-3,5-di(2′-pyridyl)-4-amino-1,2,4-triazole (L4 ) in a 1:2 ratio gives the new complexes [(η 6-arene)RuCl(L)]+ [arene=C6H6 (with L=L1(1), L2(3), L4(7), with PF6 − as a counter ion, and L4 (6), with Cl− as a counter ion) or p-cymene with L=L1(2), L2(4), L3(5), L4(8) with PF6 − as a counter ion]. All complexes were fully characterized using 1H and 13C NMR, elemental analyses, UV/Vis and IR spectroscopy. The single crystal X-ray structures of ligand L2 and complex 1 have been determined. The structure of 1 has the Ru atom coordinated with the arene group and to the N,N′-bidentate ligand and to the Cl atom. The arene group occupies the apex, while the ligand and the Cl atom are at the base of a pseudo-octahedral three-legged piano stool. The cytotoxicity of these mononuclear complexes was established in the human epithelial colorectal adenocarcinoma cell line (Caco-2) and for selectivity in the non-cancerous human embryonic kidney cell line (HEK293), using 5-fluorouracil (5-FU) as the reference anticancer drug. Compounds 1 and 7 were relatively inactive toward the Caco-2 tumor cells (IC50>200), while complexes 2–5 showed moderate anti-proliferative properties (IC50>100–200). Compound 6, however, displayed better anti-proliferative properties with an IC50 value lower than that of the reference drug, 5-FU, and was therefore further investigated for its antimicrobial activity against six Gram-positive and four Gram-negative bacteria.

Crystal structure of 5,11,17,23-tetra(tert-butyl)-25,26,27,28-tetrahexoxycalix[4]arene, C68H104O4

C68H104O4, monoclinic, P21/n (no. 14), a = 19.4442(12) Å, b = 16.8522(11) Å, c = 38.048(3) Å, β = 92.400(1)°, V = 12456.4(14) Å3, Z = 8, R gt(F) = 0.0488, wR ref(F 2) = 0.1326, T = 153 K.

Crystal structure of (η 6-benzene)-(N-(2,6-dimethylphenyl)-1-(pyridin-2-yl)methanimine-κ2 N,N′)ruthenium(II) perchlorate monohydrate, C20H20Cl2N2O5Ru

C20H20Cl2N2O5Ru, monoclinic, P1̅ (no. 2), a = 8.7921(2) Å, b = 11.2515(3) Å, c = 11.7014(3) Å, α = 103.752(1)°, β = 107.296(1)°, γ = 98.562(1)°, V = 1043.01(5) Å3, Z = 2, R gt(F) = 0.0198, wR ref(F 2) = 0.0553, T = 173 K.

Crystal structure of chlorido-(η6–1-isopropyl-4-methyl benzene)-(1-(pyridin-2-yl)-N-(p-tolyl)methanimine-κ2 N,N′)ruthenium(II) hexafluorophosphate(V), C23H26ClF6N2PRu

C23H26ClF6N2PRu, triclinic, P1̅ (no. 2), a = 8.9950(6) Å, b = 11.1669(8) Å, c = 12.4128(9) Å, α = 80.520(2)°, β = 87.5360(10)°, γ = 86.3200(10)°, V = 1226.59(15) Å3, Z = 2, R gt(F) = 0.0267, wR ref(F 2) = 0.0622, T = 173(2) K.

PdCuCeO–TPAB: a new catalytic system for quasi-heterogeneous Suzuki–Miyaura cross-coupling reactions under ligand-free conditions in water

PdCuCeO was applied for Suzuki–Miyaura coupling in pure water. The catalyst was highly active (TOF > 3000 h⁻¹) and could be reused.

Crystal structure of 3,6-di-2-pyridinyl-4-pyridazine carbonitrile, C15H9N5

C15H9N5, monoclinic, P21/c (no. 14), a = 8.9817(4) Å, b = 11.5791(19) Å, c = 12.065(2) Å, β = 102.289(4)°, V = 1226.03(3) Å3, Z = 4, R gt (F) = 0.0533, wR ref (F 2 ) = 0.1512, T = 173(2) K.